Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma

Official title

A Pilot Study of HIF-Mediated Gene Expression Changes in Casdatifan-Treated Refractory Renal Cell Carcinoma

Overview

This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies. The study will assess changes in HIF2-regulated gene expression through RNA sequencing of serial tumor biopsies obtained at baseline, during treatment, and at progression. Blood samples will also be collected for future analyses.

Detailed description

Casdatifan will be provided by Arcus. No additional therapeutic agents will be administered as part of this protocol.

Casdatifan will be taken orally at a fixed dose of 100 mg once daily, with or without food, on a continuous schedule beginning on Cycle 1, Day 1. Treatment will continue until radiographic disease progression or intolerable toxicity, per protocol-defined discontinuation criteria.

Two dose reductions will be permitted in the event of drug-related adverse events, per protocol-defined criteria:

* Reduced dose (-1): 50mg once daily * Reduced dose (-2): 25mg once daily Treatment will be discontinued if toxicity is not manageable at this reduced dose.

To support exploratory biomarker analyses, fresh tumor tissue and peripheral blood will be collected at up to three time points: baseline (prior to treatment), during treatment (on Cycle 3 Day 1 ± 14 days) and at end of treatment (±14 days window), if clinically feasible.

Tumor assessments will be performed via CT imaging every 12 weeks and evaluated using investigator-assessed RECIST v1.1 criteria.

Interventions

• Drug casdatifan
  Casdatifan will be taken orally at a fixed dose of 100 mg once daily, with or without food, on a continuous schedule beginning on Cycle 1, Day 1.

Primary outcome measures

• To determine the change in expression of predefined HIF2-regulated target genes in metastatic tumor tissue following casdatifan therapy in a refractory ccRCC population. [Time frame: 1 year]

Secondary outcome measures (2)

• To assess changes in global tumor gene expression following casdatifan treatment. [Time frame: 1 year]
• To identify differences in baseline and on-treatment HIF-mediated gene expression between objective responders and non-responders. [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

• Signed and dated written informed consent.
• Male or female ≥ 18 years of age on the day of signing informed consent.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Histologically confirmed metastatic clear cell renal cell carcinoma (ccRCC)
• Patients must have received at least one immune oncology (IO) agent and at least one VEGF-targeted therapy (alone or in combination)
• Measurable tumor burden which can be followed by computed tomography (CT) scan or magnetic resonance imaging (MRI), based on RECIST 1.1 as assessed by the local site investigator
• At least one metastatic lesion that is amenable to percutaneous biopsy
• Adequate organ and bone marrow function resulted ≤ 28 days prior to first dose of protocol-indicated treatment:

• Absolute neutrophil count (ANC) ≥ 1500/µL.
• Platelets ≥ 100,000/µL.
• Hemoglobin ≥ 10.0 g/dL or ≥ 6.2 mmol/L.
• Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min (as calculated by the Cockcroft-Gault Formula or calculated/measured by an alternative established institutional standard consistently applied across participants).
• Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN), or direct bilirubin ≤ ULN for participants with total bilirubin > 1.5 xULN.
• AST (SGOT) and ALT (SGPT) ≤ 2.5 times institutional upper limit of normal (ULN)
• Women must not be breastfeeding and further agree to not breastfeed during study treatment; and for at least 7 days after patient's final dose of casdatifan.
• A woman of childbearing potential (WOCBP) - see Appendix 3 for definition of WOCBP - must have a negative serum or urine pregnancy test during screening within 28 days prior to receiving first dose of protocol-indicated treatment, and must agree to follow instructions for using acceptable contraception (Appendix 3) from the time of signing consent, and until at least 7 days after her final dose of casdatifan.
• Men must refrain from donating sperm for at least 7 days after patient's final dose of casdatifan.
• A man able to father children (see Appendix 3 for definition) who is sexually active with a WOCBP must agree to follow instructions for using acceptable contraception (Appendix 3), from the time of signing consent, and until at least 7 days after his final dose of casdatifan.
• No exercise-induced desaturation on a 6-minute walk test, defined as a blood oxygen saturation by pulse oximetry ≤ 88%.
• No active pneumonitis at screening as assessed by CT scan.
• No medical history of severe chronic obstructive pulmonary disease (COPD).
• If a participant has CNS metastases the participant must meet the following criteria:

• Participants with previously treated brain metastases may participate provided they are clinically stable and without steroid treatment for at least 14 days prior to the first dose of study treatment. Participants with carcinomatous meningitis are excluded.

Exclusion criteria

• Prior treatment with HIF 2α inhibitors (e.g. belzutifan or related agents)
• Is currently participating in or within 2 weeks prior to receiving first dose of study treatment in a study of an investigational agent or investigational device.

• Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 2 weeks after the last dose or last exposure to the previous investigational agent or investigational device.
• Known severe hypersensitivity (≥ Grade 3) to any of the excipients of casdatifan.
• History of myocarditis or pericarditis or other known underlying heart disease that is clinically significant by investigator judgment (for example, cardiomyopathy, congestive heart failure with New York Heart Association \[NYHA\] functional classification III or IV, symptomatic arrhythmia not controlled by medication, unstable angina, history of acute myocardial infarction). History of cerebrovascular accident (including TIA) within the past 6 months (24 weeks) prior to starting study treatment.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection/sepsis, interstitial lung disease, recent hospitalizations with unresolved symptoms, poorly controlled hypertension, or psychiatric illness/social situations that would limit compliance with study requirements.
• Inability to swallow study treatment.
• Contraindications to biopsy (e.g. bleeding diathesis, uncorrectable coagulopathy)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• Vanderbilt University Medical Center — Nashville

Identifiers

NCT: NCT07748988 · VICCURO25-03

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗